Wholly owned subsidiary KIMS Swastha signs hospital management and sub-lease deal for 210-bed facility, with option to acquire majority stake later
Minister highlights scope for domestic manufacturing during his meeting with Dr Niti Pall, President-elect, International Diabetes Federation
Institute signs four MoUs, launches two products and marks 75 years with renewed focus on lab-to-market commercialisation
The company said the increase—up to 20%—takes effect immediately, or as current contracts allow
A joint position paper warns that Europe is the only major global region without a dedicated biomanufacturing initiative
The approach, which could significantly reduce the number of rats used in certain dose-range finding studies
The move represents a significant milestone in Lupin’s strategy to expand its specialty care portfolio and strengthen its presence in Europe
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
The impact on Phase III trials is particularly significant, as these later-stage studies involve larger, committed patient populations and represent years of investment
Sugammadex injection is bioequivalent to Merck’s Bridion injection for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery
Subscribe To Our Newsletter & Stay Updated
